Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nanobiotix's IPO Triggers Calls In Europe For More "Citizen Funding"

This article was originally published in The Pink Sheet Daily

Executive Summary

Nanotechnology which amplifies the antitumor effects of radiotherapy is being developed by French company Nanobiotix, which has just completed an IPO on NYSE Euronext in Paris, following investment by the general public in France via citizen's funds.

You may also be interested in...

Carlina Develops Anticancer Nanocapsules For Pets And Patients

French drug delivery firm Carlina is developing new lipid-based nanoparticle formulations of cancer drugs for pets and patients, and aims to build a proprietary pipeline with the help of collaborations with other companies.

British Biotechs Urge U.K. Government To Import French Private Investment Vehicle

British biotech companies want the U.K. government to adopt a French method of funneling funds into the cash-strapped sector from private individuals in return for favorable rates of investment tax, on grounds that a version of France’s long-running Fonds Commun de Placement dans l'Innovation is needed for small-to-medium-sized biopharma companies in Britain to tap successfully into long-term seed capital.

Peanut Allergy Targeted By DBV Technologies As It Raises $55 Million In Second Euro Biotech IPO This Year

France's DBV Technologies lists on NYSE Euronext in Paris and targets peanut and other food allergies for the first clinical studies of its epicutaneous patches as allergy desensitization therapies.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts